Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Biografy

Federico Zambon studied at the University of Padua in Italy for both his Undergraduate Degree in Molecular Biology and his Master Degree in Health Biology. He then joined the laboratory of Professor Wade-Martins in the Department of Physiology, Anatomy and Genetics at the University of Oxford. For his DPhil, Federico studied α-Synuclein pathology in Parkinson's disease using iPSC-derived dopaminergic neurons. He then moved to University College London in the laboratory of Prof Michael Duchenne as a postdoc, to study GBA1 mutations and their effect on mitochondrial function and homeostasis using iPSC-derived dopaminergic neurons.
In 2018, Federico joined Oxford Biomedica, a lentiviral-based gene therapy company developing therapies for neurodegenerative disorders, macular degeneration and liver metabolic disease, before returning to the University of Oxford in 2024 to join the Institute of Development and Regenerative Medicine in the team lead by Dr Carlo Rinaldi.

Research groups

Federico Zambon

DPhil


Staff Scientist